<DOC>
	<DOCNO>NCT01992016</DOCNO>
	<brief_summary>This pilot clinical trial study fludeoxyglucose F18 ( FDG ) -positron emission tomography ( PET ) image patient prostate cancer treat ranolazine . Diagnostic procedure , FDG-PET , may help find prostate cancer find far disease spread . Giving ranolazine may enhance FDG-PET image increase amount glucose available uptake scan .</brief_summary>
	<brief_title>A Pilot Study Enhance F18 FDG-PET Imaging Prostate Cancers With Metabolic Inhibitor Ranolazine</brief_title>
	<detailed_description>PET scan traditionally good detect prostate cancer . This prostate cancer cell take glucose well signal weak . The ability PET image detect cancer require cancer cell take glucose cell . Different method test see improve detection prostate cancer use PET scan . Ranolazine drug already approve FDA treatment chronic chest pain people heart disease . Ranolazine study laboratory University Colorado Denver , Anschutz Medical Campus . Ranolazine add prostate cancer cell grow petri dish animal laboratory . It show increase glucose uptake prostate cancer cell . The goal study see patient take ranolazine good PET image prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . Adults 18 year age . 3 . Histological cytologically confirm prostate adenocarcinoma . 4 . Arm 1 patient must treatmentnaïve , Gleason ≥ 7 prostate cancer base transrectal ultrasound ( TRUS ) biopsy , localized disease , decide undergo radical prostatectomy ( open robotic ) definitive treatment prostate cancer . 5 . Arm 2 patient must lymph node , soft tissue , bone , visceral metastatic disease measure ≥ 1 cm ( lytic component bone ) , document either CT MRI image within 6 week sign consent . Arm 2 patient may hormonesensitive castrateresistant disease may receive treatment hormonal therapy . 6 . For Arm 1 patient , time TRUS prostate biopsy plan first study PET scan must ≥ 1 month . For patient undergone prior prostate mapping biopsy , time map biopsy plan first study PET scan must ≥ 2 month . 7 . For Arm 1 patient , participation study , opinion treat physician , introduce delay surgery would adversely affect patient . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 9 . Fasting blood glucose ≤ 120 mg/dL . 10 . Adequate renal function ( Creatinine ≤ 1.5 X ULN ) 11 . Adequate hepatic function ( bilirubin &lt; 1.5 X upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &lt; 1.5 X ULN , aspartate aminotransferase ( AST ) &lt; 1.5 X ULN , albumin ≥ 3 g/dL . For patient know bone metastasis , alkaline phosphatase &lt; 5 X ULN acceptable . 12 . Must able take oral medication without crush , dissolve chew tablet . 13 . Written authorization use release health research study information obtain . 14 . Patients partner childbearing potential must willing use method birth control adequate barrier protection study 1 week last dose ranolazine . 1 . Have small cell carcinoma neuroendocrine component &gt; 50 % . 2 . Have history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption ranolazine . 3 . Documented hypersensitivity component ranolazine ( Ranexa® ) pill . 4 . Need medication : 1. strong cytochrome P450 , family 3 , subfamily A ( CYP3A ) inhibitor ( e.g . ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) , 2. moderate CYP3A inhibitor ( e.g . diltiazem , verapamil , erythromycin , fluconazole , grapefruit juice grapefruitcontaining product ) , 3 . CYP3A inducer ( e.g . rifampin , rifabutin , rifapentine , phenobarbital , phenytoin , carbamazepine , St. John 's wort ) , 4 . CYP3A substrates narrow therapeutic range ( e.g . cyclosporine , tacrolimus , sirolimus ) , 5 . Pgp inhibitor substrates ( e.g . cyclosporine , digoxin ) , 6. polypeptide 6 ( CYP2D6 ) substrates ( e.g . tricyclic antidepressant antipsychotic ) , 7. simvastatin dos &gt; 20 mg/day . 5 . Have correct QT interval ( QTc ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) 12lead electrocardiogram . 6 . Poorly control diabetes , hemoglobin A1c ( Hgb A1C ) &gt; 9 random blood glucose &gt; 250mg/dL . 7 . Active symptomatic viral hepatitis chronic liver disease . 8 . Clinically significant heart disease evidence : 1. myocardial infarction , 2. arterial thrombotic event past 6 month , 3. severe unstable angina , 4 . New York Heart Association Class IIIIV heart disease 5. cardiac ejection fraction measurement &lt; 50 % . 9 . Active infection require antibiotic . 10 . Major surgery radiation treatment within 3 month . 11 . Cytotoxic chemotherapy within 4 week . 12 . Immunotherapy within 6 month . 13 . Any prior therapy Radium223 , Samarium , Strontium . 14 . Arm 1 patient may receive prior luteinizinghormonereleasing hormone ( LHRH ) agonists/antagonists , antiandrogens , chemotherapy prostate cancer . 5alpha reductase inhibitor ( finasteride , dutasteride ) may allow . 15 . Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>F18 FDG-PET</keyword>
	<keyword>Imaging</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Soft tissue metastasis</keyword>
</DOC>